drugset / Trial / NCT03119714
Pemirolast in Allergen Challenge (PEMAG)
Phase 2
Terminated
1 enrolled
Karolinska University Hospital
Dept. Respiratory Medicine, University of Amsterdam, Amsterdam · collabDiv Clinical Pharmacology, Karolinska University Hospital · collabKarolinska Institutet · collabOccupational and Environmental Medicine, Sahlgrenska UH, Gothenburg · collabUnit for Chemistry II, Department of Medical Biochemistry, Karolinska Institutet · collab
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study is to establish the influence of the non-steroidal candidate-drug pemirolast on allergen-induced airway obstruction and inflammation in allergic subjects with asthma. Pemirolast is an orally available inhibitor of the release of mast cell mediators. The study will therefore test the hypothesis that global inhibition of the mast cell, resulting in decreased production of most of its mediator molecules, will provide a highly significant anti-asthmatic effect.
Timeline
- Start
- 2016-11
- Primary completion
- 2018-02
- Completion
- 2018-02
Outcome
Outcome not reported
Stopped: “Due to results from other studies regarding efficacy of pemirolast”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pemirolast | Small molecule | 200 mg | Oral |